[HTML][HTML] Predictors of response, progression-free survival, and overall survival in patients with lung cancer treated with immune checkpoint inhibitors
RM Memmott, AR Wolfe, DP Carbone… - Journal of Thoracic …, 2021 - Elsevier
… lung cancer. Studies have revealed improved objective response rates, progression-free
survival, and overall survival … subset of unselected patients with lung cancer responds to these …
survival, and overall survival … subset of unselected patients with lung cancer responds to these …
[HTML][HTML] … overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
T Mok, DR Camidge, SM Gadgeel, R Rosell… - Annals of oncology, 2020 - Elsevier
… survival (PFS) with alectinib versus crizotinib in treatment-naive ALK-positive non-small-cell
lung cancer (… We report mature PFS (cut-off: 30 November 2018) and overall survival (OS) …
lung cancer (… We report mature PFS (cut-off: 30 November 2018) and overall survival (OS) …
Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study
… Overall survival (OS) and duration of response were secondary end points. … For patients
with non‒small-cell lung cancer (NSCLC), median overall survival (OS) and 5-year survival …
with non‒small-cell lung cancer (NSCLC), median overall survival (OS) and 5-year survival …
Impact of EGFR inhibitor in non–small cell lung cancer on progression-free and overall survival: a meta-analysis
… survival and may be important in the development and progression of non–small cell lung
cancer … TKIs) on progression-free survival (PFS) and overall survival (OS) in advanced NSCLC …
cancer … TKIs) on progression-free survival (PFS) and overall survival (OS) in advanced NSCLC …
Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non–small-cell lung cancer: US Food and Drug …
GM Blumenthal, SW Karuri, H Zhang… - Journal of Clinical …, 2015 - ascopubs.org
… classification and treatment of lung cancer. Traditionally, lung cancer had been classified
based on histology. With the evolution of technologies to sequence the cancer genome and an …
based on histology. With the evolution of technologies to sequence the cancer genome and an …
Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor …
JCH Yang, LV Sequist, MH Schuler, T Mok… - 2014 - ascopubs.org
8004^ Background: Afatinib (A) is an oral, irreversible ErbB family blocker of EGFR, HER2,
ErbB3 and ErbB4 signalling. LL3 compared A with cisplatin/pemetrexed in 345 pts recruited …
ErbB3 and ErbB4 signalling. LL3 compared A with cisplatin/pemetrexed in 345 pts recruited …
[HTML][HTML] Quitting smoking at or around diagnosis improves the overall survival of lung cancer patients: a systematic review and meta-analysis
Introduction Lung cancer (LC) remains a disease with poor prognosis despite recent advances
in treatments. Here, we aimed at summarizing the current scientific evidence on whether …
in treatments. Here, we aimed at summarizing the current scientific evidence on whether …
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of …
A Mauguen, JP Pignon, S Burdett, C Domerg… - The lancet …, 2013 - thelancet.com
… of chemotherapy and radiotherapy for lung cancer is overall survival. Although reliable and
… We assessed the correlations between potential surrogate endpoints and overall survival at …
… We assessed the correlations between potential surrogate endpoints and overall survival at …
[HTML][HTML] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, EH Tan, K O'Byrne, L Zhang, V Hirsh… - Annals of …, 2017 - Elsevier
… blocker, afatinib, significantly improved progression-free survival (PFS), time-to-treatment …
lung cancer (NSCLC). Here, we present primary analysis of mature overall survival (OS) data. …
lung cancer (NSCLC). Here, we present primary analysis of mature overall survival (OS) data. …
[HTML][HTML] A validated prediction model for overall survival from stage III non-small cell lung cancer: toward survival prediction for individual patients
C Oberije, D De Ruysscher, R Houben… - International Journal of …, 2015 - Elsevier
… In addition, more accurate prediction of survival would allow … and predictive factors for lung
cancer survival. By contrast, … and validate a prediction model for survival of stage III NSCLC …
cancer survival. By contrast, … and validate a prediction model for survival of stage III NSCLC …
相关搜索
- overall survival of lung cancer patients
- cell lung cancer
- small cell lung cancer meta analysis
- lung cancer survival data
- lung cancer immune checkpoint inhibitors
- small cell lung cancer patients
- lung cancer open label
- lung cancer pooled analysis
- early stage lung cancer
- lung cancer individual patient data
- lung cancer first line treatment
- lung cancer systematic review
- comorbidity and treatment lung cancer survival
- treatment advances lung cancer survival
- lung cancer five year overall survival
- small amount lung cancer survival